Showing results (111-120 of 412) with videos related to

Sort By:
Pageof 42
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Blood Advances|December 29, 2021
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapyJorge J Castillo, Shayna R Sarosiek, Joshua N Gustine, et al.
Blood|May 5, 2016
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibGuang Yang, Sara J Buhrlage, Li Tan, et al.
British Journal of Haematology|July 6, 2016
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaJorge J Castillo, Ramon Garcia-Sanz, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|September 6, 2018
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaJoshua N Gustine, Nicholas Tsakmaklis, Maria G Demos, et al.
Seminars in Oncology|April 30, 2003
The malignant clone in Waldenstrom's macroglobulinemiaJitra Kriangkum, Brian J Taylor, Michael J Mant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2006
Infectious complications associated with alemtuzumab use for lymphoproliferative disordersStanley I Martin, Francisco M Marty, Karen Fiumara, et al.
Blood|February 7, 2004
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral bloodJitra Kriangkum, Brian J Taylor, Steven P Treon, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2013
Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemiaChristina K Tripsas, Christopher J Patterson, Sacha N Uljon, et al.
Pageof 42